BioCentury | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

...Tumor protein p63 Inhua Muijrers-Chen, Associate Editor Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Avadomide...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Li, Staff Writer Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Cellular...
BioCentury | Aug 3, 2018
Preclinical News

Mechanism identified behind thalidomide-induced birth defects

...Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Dana-Farber...
BioCentury | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

...CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Gilead...
BioCentury | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

...CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Gilead...
BioCentury | May 23, 2016
Product Development

Provoking a response

...of industry veterans, including Allen, who co-founded Clovis Oncology Inc. and was previously CMO of Pharmion Corp....
BioCentury | May 2, 2016
Company News

Celgene sales and marketing update

...MDS) and chronic myelomonocytic leukemia (CMML). Celgene gained rights to Vidaza through its acquisition of Pharmion Corp....
BioCentury | Nov 9, 2015
Clinical News

Vidaza azacitidine regulatory update

...MDS) and chronic myelomonocytic leukemia (CMML). Celgene gained rights to Vidaza through its acquisition of Pharmion Corp....
BioCentury | Oct 26, 2015
Finance

Neo is the time

...With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer...
...of Friday, its market cap was $3.7 billion. Prior to that, he was CMO of Pharmion...
...to president and CEO Patrick Mahaffy, who is Gritstone's chairman. "It's the same team as Pharmion...
BioCentury | Oct 21, 2015
Top Story

Gritstone raises $102M series A

...was EVP of clinical and preclinical development and CMO. Before Clovis, he was CMO at Pharmion Corp....
...Gritstone Chairman Patrick Mahaffy is president, CEO and a co-founder of Clovis. Mahaffy also founded Pharmion...
Items per page:
1 - 10 of 451
BioCentury | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

...Tumor protein p63 Inhua Muijrers-Chen, Associate Editor Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Avadomide...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Li, Staff Writer Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Cellular...
BioCentury | Aug 3, 2018
Preclinical News

Mechanism identified behind thalidomide-induced birth defects

...Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Dana-Farber...
BioCentury | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

...CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Gilead...
BioCentury | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

...CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Gilead...
BioCentury | May 23, 2016
Product Development

Provoking a response

...of industry veterans, including Allen, who co-founded Clovis Oncology Inc. and was previously CMO of Pharmion Corp....
BioCentury | May 2, 2016
Company News

Celgene sales and marketing update

...MDS) and chronic myelomonocytic leukemia (CMML). Celgene gained rights to Vidaza through its acquisition of Pharmion Corp....
BioCentury | Nov 9, 2015
Clinical News

Vidaza azacitidine regulatory update

...MDS) and chronic myelomonocytic leukemia (CMML). Celgene gained rights to Vidaza through its acquisition of Pharmion Corp....
BioCentury | Oct 26, 2015
Finance

Neo is the time

...With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer...
...of Friday, its market cap was $3.7 billion. Prior to that, he was CMO of Pharmion...
...to president and CEO Patrick Mahaffy, who is Gritstone's chairman. "It's the same team as Pharmion...
BioCentury | Oct 21, 2015
Top Story

Gritstone raises $102M series A

...was EVP of clinical and preclinical development and CMO. Before Clovis, he was CMO at Pharmion Corp....
...Gritstone Chairman Patrick Mahaffy is president, CEO and a co-founder of Clovis. Mahaffy also founded Pharmion...
Items per page:
1 - 10 of 451